This document discusses physician attitudes and practices related to smoking cessation. It finds that while guidelines recommend doctors help all patients quit smoking, many doctors find cessation activities too time-consuming or lack knowledge to assist. Several studies also show doctors miss opportunities to provide smoking cessation advice. The potential public health impact of physician intervention is enormous, but increased efforts are needed to improve physician assistance and increase their familiarity with cessation resources.
This presentation aids a Health and Wellbeing Board session on developing prevention across the health and social care system, in answer to financial challenges and the NHS FIve Year Forward View
This presentation aids a Health and Wellbeing Board session on developing prevention across the health and social care system, in answer to financial challenges and the NHS FIve Year Forward View
Breathlessness and parity of esteem: what matters to whom? - Dr Louise Restrick, London Respiratory Network Lead, Integrated Consultant Respiratory Physician, Whittington Health and Islington CCG
Presentation from the Breathlessness Symposium held in London on 1 July 2014
Public Health campaigns update (breathlessness and lung cancer) - James Brandon, Head of Marketing, Public Health England
Presentation from the Breathlessness Symposium held in London on 1 July 2014
Symptom-led diagnostic services for breathlessness: real life examples - Hilary Walker, Head of Programmes, Living Longer Lives, NHS Improving Quality and Wendy Fairhurst, Nurse Partner, Marus Bridge Practice
Better outcomes, better value: integrating physical and mental health into clinical practice and commissioning
Tuesday 24 June 2014: 15 Hatfields, Chadwick Court, London
Addiction Medicine: Closing the Gap between Science and PracticeCenter on Addiction
These slides accompany CASAColumbia's report, Addiction Medicine: Closing the Gap between Science and Practice, published in June 2012, which found that, despite the prevalence of addiction, the enormity of its consequences, the availability of effective solutions and the evidence that addiction is a disease, both screening and early intervention for risky substance use are rare, and only about 1 in 10 people with addiction involving alcohol or drugs other than nicotine receive any form of treatment.
Introduction to breathlessness symposium - Professor Mike Morgan, National Clinical Director for Respiratory Services
Presentation from the Breathlessness Symposium held in London on 1 July 2014
Detecting breathlessness and structured assessment in primary careNHS Improving Quality
Detecting breathlessness and structured assessment in primary care - Dr Noel Baxter, GP and Clinical Commissioner, Southwark CCG and PCRS Executive
Presentation from the Breathlessness Symposium held in London on 1 July 2014
TYA and Adult Late Effects Service at UCLHUCLPartners
Presentation by Victoria Grandage of University College London Hospitals NHS Foundation Trust at the London Cancer Children, Teenager and Young Adults Study Day, held on 25 July 2013.
Transition: paediatric to TYA to adult follow up services - a nursing perspe...UCLPartners
Presentation by Susan Mehta of University College London Hospitals NHS Foundation Trust at the London Cancer Children, Teenager and Young Adults Study Day, held on 25 July 2013.
It is a brief discription of cancer . In this ppt some important key words are discribed. It is very important for everyone.you should download the ppt for your personal and educational purposes.cancer is the two types first one is benins tumor and second one is malignant tumor. Benine tumor is the tumor that where it is originated and at the end it is present here but malignant tumor is that it sperate whole body.
Breathlessness and parity of esteem: what matters to whom? - Dr Louise Restrick, London Respiratory Network Lead, Integrated Consultant Respiratory Physician, Whittington Health and Islington CCG
Presentation from the Breathlessness Symposium held in London on 1 July 2014
Public Health campaigns update (breathlessness and lung cancer) - James Brandon, Head of Marketing, Public Health England
Presentation from the Breathlessness Symposium held in London on 1 July 2014
Symptom-led diagnostic services for breathlessness: real life examples - Hilary Walker, Head of Programmes, Living Longer Lives, NHS Improving Quality and Wendy Fairhurst, Nurse Partner, Marus Bridge Practice
Better outcomes, better value: integrating physical and mental health into clinical practice and commissioning
Tuesday 24 June 2014: 15 Hatfields, Chadwick Court, London
Addiction Medicine: Closing the Gap between Science and PracticeCenter on Addiction
These slides accompany CASAColumbia's report, Addiction Medicine: Closing the Gap between Science and Practice, published in June 2012, which found that, despite the prevalence of addiction, the enormity of its consequences, the availability of effective solutions and the evidence that addiction is a disease, both screening and early intervention for risky substance use are rare, and only about 1 in 10 people with addiction involving alcohol or drugs other than nicotine receive any form of treatment.
Introduction to breathlessness symposium - Professor Mike Morgan, National Clinical Director for Respiratory Services
Presentation from the Breathlessness Symposium held in London on 1 July 2014
Detecting breathlessness and structured assessment in primary careNHS Improving Quality
Detecting breathlessness and structured assessment in primary care - Dr Noel Baxter, GP and Clinical Commissioner, Southwark CCG and PCRS Executive
Presentation from the Breathlessness Symposium held in London on 1 July 2014
TYA and Adult Late Effects Service at UCLHUCLPartners
Presentation by Victoria Grandage of University College London Hospitals NHS Foundation Trust at the London Cancer Children, Teenager and Young Adults Study Day, held on 25 July 2013.
Transition: paediatric to TYA to adult follow up services - a nursing perspe...UCLPartners
Presentation by Susan Mehta of University College London Hospitals NHS Foundation Trust at the London Cancer Children, Teenager and Young Adults Study Day, held on 25 July 2013.
It is a brief discription of cancer . In this ppt some important key words are discribed. It is very important for everyone.you should download the ppt for your personal and educational purposes.cancer is the two types first one is benins tumor and second one is malignant tumor. Benine tumor is the tumor that where it is originated and at the end it is present here but malignant tumor is that it sperate whole body.
Healthcare interventions to promote and assist tobacco cessation: a review of...Georgi Daskalov
Healthcare interventions to promote and assist tobacco cessation: a review of efficacy, effectiveness and affordability for use in national guideline development
In South Africa, we’re concerned about the burden of tobacco and especially about the tactics adopted by the tobacco industry to target youth. Research shows tobacco use is often initiated and established during adolescence and young adulthood.”
Smoking remains a major preventable cause of disease and premature death globally. Read more http://www.cansa.org.za/avoid-tobacco/
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
2. Health Hazards of smoking
• Tobacco is the leading preventable cause of death in
the world today. It currently leads to the death of one
in ten adults. The number of annual deaths is expected
to increase to 8 million by 2030.
• Smoking causes a wide range of health conditions and
fatal diseases, including cancer, respiratory disease and
heart disease.
• It is the most important risk factor for chronic
obstructive pulmonary disease and lung cancer.
• Exposure to second-hand tobacco smoke harms health
and worsens existing health problems, including
respiratory conditions. It causes diseases such as lung
cancer, coronary heart disease and cardiac death
3.
4.
5.
6.
7. Smoking burden
Globally
• The tobacco epidemic is one of the biggest public
health threats the world has ever faced, killing
around 6 million people a year. More than 5
million of those deaths are the result of direct
tobacco use while more than 600 000 are the
result of non-smokers being exposed to second-
hand smoke.
Nearly 80% of the more than 1 billion smokers
worldwide live in low- and middle-income
countries, where the burden of tobacco-related
illness and death is heaviest.
8. Smoking burden
Egypt:
• It is estimated that approximately 20% of the
population uses tobacco products daily.
• Cigarettes are the most common form of
tobacco consumption in Egypt, with an
estimated 20 billion cigarettes smoked
annually in the country.
• After cigarettes shisha are the most common
form of tobacco consumption.
9.
10. Smoking cessation
• Smoking cessation significantly reduces morbidity
and mortality.
• Brief tobacco cessation counseling interventions,
including screening, brief counseling (3 min or
less), and/or pharmacotherapy; have proven to
increase tobacco abstinence rates.
• It’s recommended that clinicians screen all adults
for tobacco use and provide tobacco cessation
interventions for those who use tobacco products
11. Golden standards for initiating
smoking cessation is the 5 As
Asking about tobacco use,
Advising tobacco users to quit,
Assessing readiness to make a quit attempt,
Assisting with the quit attempt,
Arranging follow-up care.
12. Cessation Options
• Counseling. . Intensive counseling is associated
with a 22% rate of quitting, and even minimal
(<3 minutes) counseling is associated with a
13% quit rate.
Pharmacotherapy. Two general classes of drugs
are approved by FDA for cessation:
1-Nicotine replacements products (NRTs)
2-Psychotropic drugs.
25 November 2015 Moustapha Mounib 12
13. Smoking Cessation Interventions
There are 5 basic ways to help smoking quit: increase the
price of a pack of cigarettes by increasing taxes; pass
clean indoor air legislation that bans smoking in public
places; create and disseminate effective counter-
marketing messages about smoking-in the media or as
graphic package displays; ban tobacco advertising and
promotion; and provide cessation aids.
25 November 2015 Moustapha Mounib 13
14. Role of physicians
• While guidelines recommend all doctors to ask their patients
about their smoking habits and, in case they smoke, offer
cessation advice, limited data are available about doctors'
attitudes toward these recommendations
• Physicians can contribute largely to efforts to reduce smoking
and remain one of the most important sources of information
on health risks for patients and their families.
• Many smokers will visit a physician each year , and physician
advice and encouragement have been shown to increase the
number of patients who will attempt and succeed in quitting
smoking.
• Recent studies suggest that physician interventions have the
potential to increase abstinence rates to 30% from only 7%
among adult smokers attempting to quit on their own
15.
16. Norwegian hospital doctors
• 23% of the doctors found it too time consuming to ask if
the patient smoked, and approximately 35% found it too
time consuming to inform or offer help on smoking
cessation.
• About 25% of the doctors felt that they did not possess
enough knowledge to help the patient to stop smoking, and
65% of the doctors preferred to refer to a specialist for this.
• 28% of the doctors did not see it as their task to help the
patient to stop smoking, while 32% did not think it is worth
the effort to offer the patient help to stop smoking.
• In conclusion, about one-quarter to one-third of Norwegian
hospital doctors seem to disagree with current guidelines
that all doctors should address their patients' smoking
habits
17. University of Washington School of Medicine
• A sample of 8229 smokers aged 18 years and
older who made at least one visit to a physician in
the past year.
CONCLUSIONS:
• Physicians continue to miss opportunities to
provide smoking cessation advice, a potentially
lifesaving intervention. Given the adverse health
consequences of tobacco use and the
demonstrated benefit of advice to quit,
physicians need to improve their cessation
counseling efforts.
18. A study by the Cancer Control Science Program,
National Cancer Institute, Maryland
The potential public health impact of physician
intervention with smoking patients is enormous.
Even with very modest expectations of cessation
rates, 100,000 physicians using effective
intervention can produce over 3 million new ex-
smokers in the United States each year. In
conjunction with other community-based
tobacco control efforts, this physician-lead effort
will result in a marked reduction in the morbidity
and mortality caused by smoking and, thus,
control of "the most important public health
issue of our time."
19. KAP Family Physicians Regarding Smoking
Cessation Counseling in Suez Canal University
• The present study showed limited knowledge
and practice of family physicians regarding
smoking cessation counseling.
• Training and lack of time were among the
barriers that call for organization support.
• Further, interventional researches are needed
to improve and re-evaluate quality of smoking
cessation counseling using direct observation
of practice.
20. Conclusions
Decreasing tobacco use will require greater activity on the part
of the physicians in cessation activities. This will require
increased familiarity with available resources as well as
sustained efforts to improve these resources. Specifically,
several areas for improvement exist, including:
Increase the availability and use of tobacco control tools
• Increase the number of smoking cessation services
• Promote physician familiarity with tobacco control
resources as well as how patients can access these services
• Provide physicians with additional information on quitlines
and web based resources Increase physician assistance to
patients who smoke to reduce their use of tobacco
21. Conclusions
Increase physician assistance to patients who
smoke to reduce their use of tobacco
• Encourage medical practices to require
documentation of activities undertaken to help
patients quit smoking, e.g., documentation of
treatment strategies discussed with patients
• Improve physician-patient communication
around tobacco use
Improve coverage for tobacco control treatment,
services, and physician time
• Expand insurance coverage to include additional
cessation treatment and support services
22. Conclusions
Increase physician knowledge of tobacco control
interventions
• Improve effectiveness of medical school curricula on
tobacco control as part of assisting patients with
behavioral changes
• Increase the availability of CME related to smoking
cessation and behavioral change
Support investment in tobacco control
• Improve linkages between physician associations and
other tobacco control stakeholders to promote
collaboration in efforts in to promote the health of
citizens in communities